 Oncolytics Biotech NASDAQ:ONCY was upgraded by ValuEngine from a hold rating to a buy rating in a report released on Friday, ValuEngine reports. A number of other equities analysts also recently commented on the stock. Canaccord Genuity restated a buy rating on shares of Oncolytics Biotech in a research note on Wednesday, March 25th. Zacks ... 